Do you want to read an article? Please log in or register.
The Magnolia Trial: Zanubrutinib, A Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Lymphoma
Related content
COMMENTED
Lymphoma
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1056/NEJMoa1914347.
Lung, Respiratory and Thoracic Cancer
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Drug Saf.
Rocco D, Battiloro C, Della Gravara L, Gridelli C
doi: 10.1007/s40264-018-0771-y.
RECOMMENDED
Lymphoma
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
★ 1
Recommended by
Alexander Meisel, Faculty Member
Lancet Oncol.
Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kazmierczak M, Opat S, Radford J, Schmitt A, Yang J, Whalen J, Agarwal S, Adib D, Salles G
doi: 10.1016/S1470-2045(20)30441-1.Visit the original publication at ncbi.nlm.nih.gov
Lymphoma
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Lancet Haematol.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA
doi: 10.1016/S2352-3026(20)30120-4.
Lymphoma
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Lancet Haematol.
Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Sharon E, Streicher H, Kahl BS, Ansell SM
doi: 10.1016/S2352-3026(20)30221-0.
LeukemiaLymphoma
Time for a New Standard: Single Agent Ibrutinib shows Long-Term Efficacy and Safety in Previously Treated MCL and CLL1-4
This healthbook SPECIAL is supported by Janssen-Cilag AG
COMMENTED
Multiple Myeloma (MM)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
★ 1
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1016/S2352-3026(20)30070-3.
Lymphoma
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Lancet.
Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T
doi: 10.1016/S0140-6736(20)31366-0.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Shi R, Filho SNM, Li M, Fares A, Weiss J, Pham NA, Ludkovski O, Raghavan V, Li Q, Ravi D, Cabanero M, Moghal N, Leighl NB, Bradbury P, Sacher A, Shepherd FA, Yasufuku K, Tsao MS, Liu G
doi: 10.1016/j.lungcan.2020.05.018.